Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes.

ABSTRACT:

Purpose

Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). We aimed to provide an extensive validation of IPSS-M.

Methods

A total of 2,876 patients with primary MDS from the GenoMed4All consortium were retrospectively analyzed.

Results

IPSS-M improved prognostic discrimination across all clinical end points with respect to IPSS-R (concordance was 0.81 v 0.74 for overall survival and 0.89 v 0.76 for leukemia-free survival,

SUBMITTER: Sauta E 

PROVIDER: S-EPMC10414702 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature